Earlier quoted context omitted.
I don't think 23andme's strongest asset point would be in direct drug discovery, but rather in helping target sub-populations for clinical trials. The SNP data that 23andme has is relatively low quality compared to proper sequencing, but (combined with their survey data) is probably at least as good, or better information available for typical clinical trial planning or screening.
> I don't think 23andme's strongest asset point would be in direct drug discovery, but rather in helping target sub-populations for clinical trials Was there an issue with targeting sub-populations for clinical trials beforehand? At an ELI5 level, if you're hoping your drug candidate will help cure disease X, you sign up patients with disease X to join your clinical trial. That's not the hard part! (source: family me…
a) If you suspect there is a significant pharmacogenetics component to what you are studying (or related to disease progression).
b) You're working on something preventative.
From a previous job I worked at (we made PCR tests), there was interest on screening for APOE genotypes to enrich an Alzheimer's drug trial - drug maker believed that APOE genotype would have a significant impact on drug performance.
But you're absolutely right that you can often (usually?) do 'enough' enriching without genetic information.